Document Classification

Section Type: RESULTS

Text: Compared with placebo, fluvastatin significantly improved flow-mediated vasodilatation to hyperemia, a hallmark of endothelial function [from 3. 8 % (-3. 9 approximately 15. 2) to 5. 9 % (-0. 3 approximately 13. 2), p = 0. 001], and attenuated plasma levels of high sensitivity C-reactive protein (hsCRP) [from 1. 3 (0. 3 approximately 7. 7) to 1. 1 mg/l (0. 2 approximately 3. 5), p = 0. 018], IL-18 [from 247. 6 (145. 4 approximately 378. 4) to 196. 4 pg/dl (90. 7 approximately 380. 2), p < 0. 001], total MMP-9 (from 58 + / - 46. 3 to 39. 4 + / - 22. 4 ng/dl, p = 0. 023), and MMP-9 activity [from 6. 4 (3. 6 approximately 27) to 5. 6 ng/dl (3. 1 approximately 13. 7)].